Takashi Yamamura Selected Research

satralizumab

1/2023	Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
10/2022	Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
5/2022	Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series.
1/2020	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
11/2019	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takashi Yamamura Research Topics

Disease

43	Multiple Sclerosis 01/2024 - 06/2003
22	Autoimmune Diseases (Autoimmune Disease) 01/2023 - 10/2003
20	Neuromyelitis Optica (Devic's Disease) 01/2024 - 03/2011
19	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 09/2023 - 10/2003
8	Inflammation (Inflammations) 10/2021 - 01/2005
6	Infections 01/2024 - 01/2011
6	Experimental Arthritis 01/2012 - 01/2004
5	Neuroinflammatory Diseases 01/2024 - 08/2009
5	AIDS-Related Complex (ARC) 08/2023 - 01/2013
5	Relapsing-Remitting Multiple Sclerosis 01/2019 - 01/2017
5	Arthritis (Polyarthritis) 01/2012 - 06/2005
4	Pain (Aches) 01/2021 - 10/2014
3	Neoplasms (Cancer) 09/2023 - 10/2007
3	Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) 09/2023 - 01/2018
2	Optic Neuritis (Retrobulbar Neuritis) 01/2024 - 01/2012
2	Disease Progression 01/2024 - 09/2021
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 05/2022 - 12/2008
2	Alzheimer Disease (Alzheimer's Disease) 05/2022 - 09/2017
2	Human Influenza (Influenza) 05/2022 - 01/2011
2	Fatigue 11/2019 - 10/2014
2	Asthma (Bronchial Asthma) 01/2011 - 09/2007
2	Colitis 09/2009 - 01/2005
2	Rheumatoid Arthritis 06/2007 - 09/2005
1	Myelitis 01/2024
1	Anaphylaxis (Anaphylactic Shock) 10/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 05/2022
1	Hepatitis E 05/2022
1	Autoimmune oophoritis 12/2021
1	Thymoma (Thymic Carcinoma) 11/2021
1	Demyelinating Diseases (Demyelinating Disease) 01/2020
1	Symptom Flare Up 01/2020

Drug/Important Bio-Agent (IBA)

13	GlycolipidsIBA 01/2024 - 01/2004
12	LigandsIBA 01/2013 - 01/2004
11	AutoantibodiesIBA 11/2020 - 06/2005
11	CytokinesIBA 01/2018 - 01/2004
8	alpha-galactosylceramideIBA 01/2008 - 01/2004
7	InterferonsIBA 01/2021 - 09/2004
6	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2024 - 03/2013
6	AntibodiesIBA 09/2023 - 01/2012
6	SphingosineIBA 06/2007 - 01/2004
5	KisspeptinsIBA 08/2023 - 01/2013
5	Neurokinin BIBA 08/2023 - 01/2013
5	satralizumabIBA 01/2023 - 11/2019
5	AntigensIBA 05/2022 - 06/2004
5	Aquaporin 4IBA 01/2015 - 03/2011
4	Peptides (Polypeptides)IBA 09/2023 - 03/2003
4	Indicators and Reagents (Reagents)IBA 09/2021 - 01/2004
4	Monoclonal AntibodiesIBA 01/2020 - 06/2005
4	tocilizumab (atlizumab)FDA Link 01/2020 - 07/2013
4	Natalizumab (Tysabri)FDA Link 06/2017 - 04/2016
4	Celecoxib (Celebrex)FDA Link 01/2013 - 02/2002
3	Immunoglobulin G (IgG)IBA 01/2024 - 01/2013
3	Gonadotropin-Releasing Hormone (GnRH)FDA Link 08/2023 - 01/2013
3	Immunosuppressive Agents (Immunosuppressants)IBA 01/2023 - 11/2019
3	AutoantigensIBA 10/2022 - 12/2004
3	SteroidsIBA 05/2022 - 07/2011
3	Dynorphins (Dynorphin)IBA 12/2021 - 01/2013
3	Biomarkers (Surrogate Marker)IBA 09/2021 - 10/2005
3	InterleukinsIBA 10/2014 - 09/2005
3	Myelin P0 Protein (Myelin Protein Zero)IBA 05/2013 - 03/2003
3	DNA (Deoxyribonucleic Acid)IBA 12/2008 - 07/2007
2	ProlactinIBA 01/2024 - 10/2019
2	Adrenergic Agents (Adrenergic Drugs)IBA 09/2023 - 11/2020
2	Cholinergic Agents (Cholinergics)IBA 09/2023 - 09/2017
2	senktideIBA 08/2023 - 01/2013
2	Galactosylceramides (Galactocerebrosides)IBA 01/2023 - 09/2004
2	Granzymes (Granzyme)IBA 05/2022 - 10/2015
2	Interleukin-4 (Interleukin 4)IBA 10/2021 - 01/2004
2	Interleukin-6 (Interleukin 6)IBA 01/2020 - 03/2011
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 12/2008
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2016 - 06/2005
2	Pheromones (Semiochemicals)IBA 01/2013 - 01/2013
2	Aquaporins (Water Channels)IBA 01/2013 - 03/2011
2	Member 2 Group A Nuclear Receptor Subfamily 4IBA 01/2013 - 04/2005
2	CollagenIBA 01/2012 - 01/2012
2	Freund's AdjuvantIBA 01/2012 - 01/2012
2	Collagen Type II (Type II Collagen)IBA 01/2012 - 01/2012
2	LipopolysaccharidesIBA 01/2012 - 06/2005
2	GhrelinIBA 08/2009 - 08/2009
2	RetinoidsIBA 06/2009 - 02/2009
2	CannabinoidsIBA 01/2008 - 04/2007
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 08/2006 - 02/2002
2	Interferon-betaIBA 05/2006 - 06/2003
2	Complementary DNA (cDNA)IBA 05/2006 - 04/2005
2	14-3-3 Proteins (14-3-3 Protein)IBA 10/2005 - 08/2004
1	Myelin Proteolipid ProteinIBA 09/2023
1	GlucocorticoidsIBA 01/2023
1	Neuropilin-1IBA 10/2022
1	Complement C5 (Complement 5)IBA 01/2022
1	AntralIBA 12/2021
1	CXC ChemokinesIBA 11/2021
1	B-Cell Activation Factor ReceptorIBA 11/2021
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 11/2020
1	Methylprednisolone FDA LinkGeneric 01/2020

Therapy/Procedure

20	Therapeutics 01/2024 - 01/2004
2	Electrodes (Electrode) 12/2021 - 01/2013
2	Plasmapheresis 10/2021 - 01/2018
2	Immunotherapy 01/2018 - 10/2007
1	Hematopoietic Stem Cell Transplantation 01/2023
1	Plasma Exchange 01/2020